Rubella

Virus

Enveloped, positive-sense ssRNA, TOGAVIRUS. ONLY togavirus with RESPIRATORY (not arthropod) transmission — rest of family = mosquito-borne alphaviruses (chikungunya etc). Why grouped with respiratory exanthems, not arboviral topics.

Postnatal (Acquired) Rubella

Clinical: “German measles” — MILDER than measles despite name similarity. Low fever + fine pink maculopapular rash (cephalocaudal spread like measles, but fades faster, LESS confluent/intense). PROMINENT LYMPHADENOPATHY: POSTERIOR AURICULAR + SUBOCCIPITAL distribution — distinctive bedside clue distinguishing from measles/other exanthems. Substantial proportion SUBCLINICAL/ASYMPTOMATIC — matters for congenital risk (infected pregnant woman may not realize infected at all). Arthralgia/arthritis: more common ADULT WOMEN than children — distinctive vs measles.

Why It Matters Despite Mildness

TERATOGENIC — pregnancy infection (esp. 1st trimester) → CONGENITAL RUBELLA SYNDROME (own topic, Congenital Infections). ENTIRE clinical significance rests on this single fact. Acute illness = trivial. Reproductive/teratogenic consequence = serious. This mismatch is why rubella gets major public-health attention despite mild acute disease.

Laboratory Diagnosis

Serology: IgM (acute/recent) vs IgG (past infection/vaccination, ASSESSES IMMUNE STATUS — pregnant woman/preconception screening, documented IgG immunity PREVENTS congenital syndrome risk). One of more clinically consequential serology tests in curriculum given pre-pregnancy screening link. RT-PCR: direct detection, PRENATAL DIAGNOSIS (amniotic fluid/fetal blood) if confirmed/suspected maternal acute infection — assesses transplacental transmission.

Treatment

NO specific antiviral. Entirely SUPPORTIVE (mild self-limited illness).

Prevention — Vaccination

Live attenuated rubella component of MMR (see Measles topic). Rationale = PREVENT CONGENITAL RUBELLA SYNDROME at population level (eliminate circulating virus susceptible pregnant women might encounter) — protects FUTURE PREGNANCIES, not primarily the vaccinated individual’s own acute illness severity. Distinctive rationale vs most curriculum vaccines.

LIVE VACCINE = CONTRAINDICATED IN PREGNANCY (see Vaccines topic). Non-immune pregnant woman: vaccinate POSTPARTUM, counsel avoid pregnancy ~1 month post-vaccination (theoretical risk, though no confirmed vaccine-strain CRS cases documented in practice).

The Virus

Rubella virus is an enveloped, positive-sense ssRNA togavirus — genuinely notable for being the only togavirus transmitted person-to-person via the respiratory route rather than by an arthropod vector, in real contrast to the rest of its viral family (which includes several mosquito-borne alphaviruses such as chikungunya), a distinction worth holding onto specifically because it explains why rubella is grouped and discussed alongside the other respiratory exanthems in this section rather than with the arboviral diseases covered under Bloodstream and Cardiovascular System Infections.

Postnatal (Acquired) Rubella

Clinical Manifestations

Postnatally acquired rubella (“German measles”) is, genuinely importantly, a considerably milder illness than measles itself despite the superficially similar name and rash — a low-grade fever and a fine, pink maculopapular rash (spreading, like measles, in a cephalocaudal pattern, though typically fading faster and less confluent/coalescent than measles’ more intense exanthem) are accompanied by prominent lymphadenopathy, classically posterior auricular and suboccipital in distribution — a genuinely distinctive, specifically useful clinical clue helping distinguish rubella from measles and other childhood exanthems at the bedside, since this particular lymph node distribution is not a typical feature of the other common causes of childhood rash. A substantial proportion of postnatal infections, genuinely notably, are subclinical or entirely asymptomatic — which matters directly for understanding congenital rubella risk (below), since an infected pregnant woman may not even realize she has been infected at all. Arthralgia/arthritis, more common in adult women than in children, is a further, genuinely distinctive feature of postnatal rubella not typically seen with measles.

Why Postnatal Rubella Matters Despite Its Mildness

The clinical significance of rubella, genuinely disproportionate to the mildness of the postnatal illness itself, rests on a single fact: rubella is teratogenic, and infection during pregnancy — particularly in the first trimester — can cause devastating fetal malformation via congenital rubella syndrome, covered as its own dedicated topic under Congenital and Perinatal Infections given its major clinical importance. Rubella receives the same level of public-health attention as far more clinically severe acute illnesses precisely because of this mismatch: the acute disease itself is trivial, but the reproductive/teratogenic consequence is genuinely serious.

Laboratory Diagnosis

Serology — IgM antibody (indicating recent/acute infection) versus IgG (indicating past infection or vaccination, and, critically, used to assess immune status in a pregnant woman or someone planning pregnancy, since documented rubella IgG immunity before conception is exactly what prevents the congenital syndrome risk described above) — is the standard diagnostic approach, and is genuinely one of the more clinically consequential serology tests covered in this curriculum precisely because of its direct link to pre-pregnancy screening and counselling. RT-PCR offers direct viral detection where needed, and is particularly relevant for prenatal diagnosis of suspected congenital infection (testing amniotic fluid or fetal blood when a pregnant woman has confirmed or strongly suspected acute rubella, to assess whether transplacental transmission has actually occurred).

Treatment

There is no specific antiviral treatment — management of postnatal rubella is entirely supportive, reflecting the illness’s generally mild, self-limited course.

Prevention: Vaccination

The live attenuated rubella component of the MMR vaccine (see Measles for the combined formulation and schedule) is highly effective and durable, and its entire public-health rationale is specifically preventing congenital rubella syndrome at the population level by eliminating circulating rubella virus that a susceptible pregnant woman might otherwise encounter — the vaccine’s value proposition is fundamentally about protecting future pregnancies rather than protecting the vaccinated individual from a clinically severe acute illness, a genuinely distinctive rationale among the vaccines covered in this curriculum, most of which are justified primarily by the severity of the acute disease they prevent in the vaccinated person themselves. Rubella vaccine is a live vaccine and is therefore contraindicated in pregnancy (see Vaccines and Immunoprophylaxis for the general live-vaccine-in-pregnancy contraindication) — a woman found to be non-immune during pregnancy is vaccinated only postpartum, with counselling to avoid pregnancy for a defined period (generally about a month) after vaccination given the theoretical risk from the live attenuated virus itself, even though no confirmed cases of vaccine-strain congenital rubella syndrome have actually been documented in practice.